Intelligence Β· Patent portfolio
Regeneron Ireland Designated Patents
Full USPTO pharma patent portfolio for Regeneron Ireland Designated β grant dates, expiration, and drug cross-links.
- Patents
- 8,292
- Expiring β€24m
- 426
Quick answer
Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months β use filters for patent-cliff planning.
-
US 10111847
Compounds and methods for modulating vascular injury
granted -
US 10113151
Composition of viral vectors in lecithin liposomes, preparation method and treatment methods
granted -
US 10106650
Reversibly crosslinked micelle systems
granted -
US 10106540
HDAC6 inhibitors and their uses
granted -
US 10105416
Methods of treating mild brain injury
granted -
US 10105392
Isolated renal cells and uses thereof
granted -
US 10107816
G-protein coupled receptor-associated diagnostics and therapeutics for B-cell chronic lymphocytic leukemia
granted -
US 10105391
Chimeric antigen receptor and methods of use thereof
granted -
US 10100367
Diagnosing and monitoring CNS malignancies using microRNA
granted -
US 10100083
Leukemia stem cell targeting ligands and methods of use
granted -
US 10100279
In vitro production of medial ganglionic eminence precursor cells
granted -
US 10098971
Library of pH responsive polymers and nanoprobes thereof
granted -
US 10098878
HIF-2Ξ± inhibitors for treating iron overload disorders
granted -
US 10098839
Hydrogel toxin-absorbing or binding nanoparticles
granted -
US 10098540
Hyperspectral imaging for detection of Parkinson's disease
granted -
US 10100317
Compositions of matter that reduce pain, shock, and inflammation by blocking linoleic acid metabolites and uses thereof
granted -
US 10092596
Tungstate treatment of the dysbiosis associated with gastrointestinal inflammation
granted -
US 10092580
Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
granted -
US 10093698
Peptide having efficacy for remedying hypopigmentation and inhibiting adipogenesis, and use of same
granted -
US 10093694
Compounds for treating eye disorders or diseases
granted -
US 10092598
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
granted -
US 10092593
Citrate-rich calcium-magnesium supplement and uses thereof
granted -
US 10092512
Compositions and methods of making brittle-matrix particles through blister pack freezing
granted -
US 10092504
Use of cellular extracts for skin rejuvenation
granted -
US 10093745
Anti-CSPG4 fusions with interferon for the treatment of malignancy
granted -
US 10093664
Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of disease
granted -
US 10087181
Compound as WNT signaling inhibitor, composition, and use thereof
granted -
US 10086114
Antimicrobial solutions with enhanced stability
granted -
US 10088485
Methods of screening compounds that can modulate NR2F6 by displacement of a reference ligand
granted -
US 10087436
Electrophysiologically mature cardiomyocytes and methods for making same
granted -
US 10087431
Methods of generating nucleic acid fragments
granted -
US 10087444
MicroRNA composition for the treatment of neuroblastoma
granted -
US 10087413
Thin film cell encapsulation devices
granted -
US 10087252
Methods and compositions for treating and preventing disease associated with Ξ±vΞ²5 integrin
granted -
US 10086091
Method of preparation of biodegradable nanoparticles with recognition characteristics
granted -
US 10086088
Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord
granted -
US 10086041
Syndecan-4 proteoliposomes for enhanced cutaneous wound healing and minimized inflammatory immune response
granted -
US 10085997
Method of treating microbial infections
granted -
US 10080749
Multi-drug therapies for tuberculosis treatment
granted -
US 10080745
Piericidin bacterial inhibitors
granted -
US 10080376
Method for enhancing postprocessing content of beneficial compounds in beverages naturally containing same
granted -
US 10082496
Targeting emopamil binding protein (EBP) with small molecules that induce an abnormal feedback response by lowering endogenous cholesterol biosynthesis
granted -
US 10081668
Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection
granted -
US 10080790
Staphylococcus aureus materials and methods
granted -
US 10080775
Peptide having skin whitening activity, and use thereof
granted -
US 10080774
Oncolytic adenovirus armed with therapeutic genes
granted -
US 10080799
Methods and compositions related to glycoprotein-immunoglobulin fusions
granted -
US 10080770
Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo
granted
Frequently asked questions
How many patents does Regeneron Ireland Designated have?
8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Regeneron Ireland Designated patents expire?
426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.
Where does this data come from?
USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.
Data attribution: Data sources Β· Patent directory